[PDF][PDF] Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation
T Peeraphatdit, J Wang, MA Odenwald, S Hu… - …, 2020 - Wiley Online Library
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint
molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies …
molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies …
[HTML][HTML] Immune checkpoint inhibitor-related hepatotoxicity: A review
D Remash, DS Prince, C McKenzie… - World journal of …, 2021 - ncbi.nlm.nih.gov
The application of immune checkpoint inhibitors (ICI) in advanced cancer has been a major
development in the last decade. The indications for ICIs are constantly expanding into new …
development in the last decade. The indications for ICIs are constantly expanding into new …
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Immune checkpoint inhibitors (ICIs) have reshaped cancer therapy. ICIs enhance T cell
activation through various mechanisms and may help reverse the exhausted phenotype of …
activation through various mechanisms and may help reverse the exhausted phenotype of …
[HTML][HTML] Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
E De Martin, JM Michot, O Rosmorduc, C Guettier… - JHEP Reports, 2020 - Elsevier
Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …
different types of cancer. Liver toxicity is one of the immune-related adverse events …
Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta‐analysis of published data
W Wang, P Lie, M Guo, J He - International journal of cancer, 2017 - Wiley Online Library
Although existing evidence from clinical trials has demonstrated manifestation of hepatic
adverse events with the use of immune checkpoint inhibitors (ICPIs), overall risks have yet to …
adverse events with the use of immune checkpoint inhibitors (ICPIs), overall risks have yet to …
Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies
JJ Jennings, R Mandaliya, A Nakshabandi… - Expert opinion on drug …, 2019 - Taylor & Francis
ABSTRACT Introduction: Immune checkpoint inhibitors (ICIs) block cytotoxic T lymphocyte
antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) …
antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/PD ligand 1 (PD-L1) …
[HTML][HTML] Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug …
A Regev, MI Avigan, A Kiazand, JM Vierling… - Journal of …, 2020 - Elsevier
Immune checkpoint inhibitors (ICIs) have shown significant efficacy in patients with various
malignancies, however, they are associated with a wide range of immune-related toxicities …
malignancies, however, they are associated with a wide range of immune-related toxicities …
Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents
DL Suzman, L Pelosof, A Rosenberg… - Liver …, 2018 - Wiley Online Library
Immune checkpoint inhibitors (ICI s) block CTLA‐4, PD‐1 and PD‐L1, or other molecules
that control antitumour activities of lymphocytes. These products are associated with a broad …
that control antitumour activities of lymphocytes. These products are associated with a broad …
[HTML][HTML] Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives
Z Liu, Y Zhu, H Xie, Z Zou - Frontiers in Pharmacology, 2023 - frontiersin.org
In recent years, cancer immunotherapy has made remarkable achievements. Immune
checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the …
checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the …
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
JR Patrinely Jr, B McGuigan, S Chandra… - …, 2021 - Taylor & Francis
Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events
(irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not …
(irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not …
相关搜索
- checkpoint inhibitors diagnosis and management
- checkpoint inhibitors risk of hepatotoxicity
- checkpoint inhibitors liver toxicity
- checkpoint inhibitors increasing use
- checkpoint inhibitors hepatocellular carcinoma
- checkpoint inhibitors immunotherapy agents
- checkpoint inhibitors cancer patients
- checkpoint inhibitors meta analysis
- checkpoint inhibitors drug development
- checkpoint inhibitors vital class
- checkpoint inhibitors evolving picture
- checkpoint inhibitors biomarkers of response
- checkpoint inhibitors mechanisms of resistance
- checkpoint inhibitors limiting factor
- checkpoint inhibitors management of toxicities
- checkpoint inhibitors management strategies